Olema Pharmaceuticals, Inc. OLMA

SAN FRANCISCO, Aug. 31, 2026 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond, today announced that the Company will participate in the following upcoming investor conferences: Citi 2026 Biopharma Back to School Conference Date and Time: September 10, 2026 at 1 p.m. ET Format: Fireside ChatLocation:

SAN FRANCISCO, Aug. 13, 2026 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond, today announced the appointment of Jason O’Byrne, MBA, as Chief Financial Officer. “We are very pleased to welcome Jason to Olema at an important time for the Company,” said Sean P. Bohen, M.D., Ph.D., President and Chief

Completed enrollment in the pivotal Phase 3 OPERA-01 trial; top-line data are now expected in the first quarter of 2027Presented initial Phase 1 clinical data for OP-3136 at the 2026 ASCO Annual MeetingAnnounced a clinical trial collaboration and supply agreement with Bayer to evaluate darolutamide in combination with OP-3136 in metastatic castration-resistant prostate cancerEnded the second quarter with $461.1 million in cash, cash equivalents, and marketable securities SAN FRANCISCO, Aug. 10,

In June 2026, Olema Pharmaceuticals, Inc. was added to multiple Russell growth benchmarks, including the Russell 2000 Growth, 2500 Growth, 3000 Growth, 3000E Growth, Small Cap Comp Growth, and Microcap Growth Index. This broad inclusion across the Russell growth family meaningfully expands Olema’s visibility with index-tracking funds and institutional investors that benchmark against these indices. Against this backdrop, we’ll examine how Olema’s broad addition across Russell growth...

Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) is one of the small-cap stocks with potential to rise 1000 percent. The company gave investors a new pipeline marker on May 21, when it reported initial Phase 1 clinical data for OP-3136, its KAT6 inhibitor, at the 2026 ASCO Annual Meeting. Olema said OP-3136 monotherapy was well-tolerated, with no dose-limiting […]

Study to evaluate OP-3136, Olema’s novel KAT6 inhibitor, in combination with darolutamide in approximately 36 patients; expected to initiate in H2 2026First clinical collaboration for OP-3136; results to inform combination strategy in metastatic prostate cancer setting SAN FRANCISCO, May 26, 2026 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of ta

Olema Pharmaceuticals (NasdaqGS:OLMA) reported preliminary Phase 1 data for oral KAT6 inhibitor OP-3136, showing anti-tumor activity in multiple advanced solid tumors. The early readout highlighted tumor shrinkage and a clean safety profile in patients with difficult-to-treat cancers. More detailed results are scheduled to be presented at the 2026 ASCO Annual Meeting. For investors tracking oncology pipelines, this update puts more attention on Olema Pharmaceuticals, which is developing...

Early ASCO data for OP-3136 pointed to encouraging anti-cancer activity with a clean safety profile, adding momentum to OLMA’s pipeline story.

OP-3136 monotherapy was well-tolerated with no dose-limiting toxicities observed and no discontinuations due to treatment-related adverse eventsOP-3136 shows evidence of anti-tumor activity across multiple solid tumor typesData support the ongoing Phase 1 evaluation of OP-3136 as a monotherapy and in combination with fulvestrant and palazestrant SAN FRANCISCO, May 21, 2026 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceuti

The ESR1 Mutated metastatic breast cancer market is witnessing significant growth driven by the rising prevalence of endocrine-resistant HR-positive/HER2-negative breast cancer and increasing adoption of precision oncology approaches. The emergence of novel therapies such as Giredestrant (Roche/Genentech), Camizestrant (AZD9833) (AstraZeneca), Palazestrant (OP-1250) (Olema Pharmaceuticals), Lasofoxifene (Sermonix Pharmaceuticals), AND-019 (Kind Pharmaceuticals), H3B-6545 (Eisai), and others is r

Top-line data from the Phase 3 OPERA-01 trial anticipated this fall; Phase 3 OPERA-02 trial continues to enroll patientsFirst clinical data from OP-3136 Phase 1 study to be presented at ASCO Ended the first quarter with $505.3 million in cash, cash equivalents, and marketable securities SAN FRANCISCO, May 12, 2026 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and comme

Olema Pharmaceuticals (OLMA) has drawn fresh attention after appointing Prakash Raman, Ph.D., to its Board of Directors. This move puts an experienced oncology and immunology dealmaker closer to the company’s pipeline decisions. See our latest analysis for Olema Pharmaceuticals. Investors have seen sharp swings in Olema’s share price, with a 5.0% 7 day share price return contrasting with a 40.3% 90 day share price decline, while the 1 year total shareholder return of roughly 2.2x points to...